Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

This week’s clinical update looks at 3 clinical trials for the treatment of sickle cell disease (SCD), relapsed or refractory blood cancers and...

In this week’s clinical update, we look at three clinical-stage CRISPR-engineered cell therapies that are under development for the treatment of acute...